Abstract
Ropivacaine, the S-(-)-enantiomer of N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide is a new long-acting local anesthetic. This review demonstrates that it is effective in brachial plexus anesthesia. It is at least as efficient as bupivacaine in terms of quality, duration of analgesia, anesthesia, and motor block. It could have some advantages over bupivacaine in terms of onset time of sensory and motor block, but this remains controversial. In single-shot brachial plexus block, it is equipotent to bupivacaine and has a similar pharmacokinetic profile. Its minimal effective concentration is 0.5percent, and the benefit of increasing its concentration to 0.75 or 1percent remains debatable. Its use during continuous brachial plexus block has been much less studied, and conflicting results involving efficacy during continuous interscalene block and inefficacy during continuous axillary block have been obtained. Further investigations are required to assess its efficacy during such block.XXXYYYZZ Z Because of lower CNS and cardiac toxicity, ropivacaine is safer than bupivacaine. It would be thus the preferred local anesthetic for brachial plexus blockade when long-lasting anesthesia and analgesia is required.
Keywords: Ropivacaine, PERIVASCULAR BRACHIAL, Single-shot Interscalene, bupivacaine
Current Topics in Medicinal Chemistry
Title: Clinical Application of Ropivacaine for the Upper Extremity
Volume: 1 Issue: 3
Author(s): F. J. Singelyn
Affiliation:
Keywords: Ropivacaine, PERIVASCULAR BRACHIAL, Single-shot Interscalene, bupivacaine
Abstract: Ropivacaine, the S-(-)-enantiomer of N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide is a new long-acting local anesthetic. This review demonstrates that it is effective in brachial plexus anesthesia. It is at least as efficient as bupivacaine in terms of quality, duration of analgesia, anesthesia, and motor block. It could have some advantages over bupivacaine in terms of onset time of sensory and motor block, but this remains controversial. In single-shot brachial plexus block, it is equipotent to bupivacaine and has a similar pharmacokinetic profile. Its minimal effective concentration is 0.5percent, and the benefit of increasing its concentration to 0.75 or 1percent remains debatable. Its use during continuous brachial plexus block has been much less studied, and conflicting results involving efficacy during continuous interscalene block and inefficacy during continuous axillary block have been obtained. Further investigations are required to assess its efficacy during such block.XXXYYYZZ Z Because of lower CNS and cardiac toxicity, ropivacaine is safer than bupivacaine. It would be thus the preferred local anesthetic for brachial plexus blockade when long-lasting anesthesia and analgesia is required.
Export Options
About this article
Cite this article as:
Singelyn J. F., Clinical Application of Ropivacaine for the Upper Extremity, Current Topics in Medicinal Chemistry 2001; 1 (3) . https://dx.doi.org/10.2174/1568026013395326
DOI https://dx.doi.org/10.2174/1568026013395326 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Increasing Incidence of Treatment Resistance in Hypertension?
Current Drug Therapy Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Current Pharmaceutical Design Speculative Considerations about Some Cardiology Enigmas
Current Cardiology Reviews Thrombotic Complications of Neonates and Children with Congenital Nephrotic Syndrome
Current Pediatric Reviews Biomaterials and Mesenchymal Stem Cells for Regenerative Medicine
Recent Patents on Biotechnology Biofilms: An Extra Hurdle for Effective Antimicrobial Therapy
Current Pharmaceutical Design An Overview of the Design, Development and Applications of Biodegradable Stents
Drug Delivery Letters Cutaneomeningospinal Angiomatosis (Cobb Syndrome) in a Young Patient
CNS & Neurological Disorders - Drug Targets The Role of Gut Glucose Metabolism in the Control of Food Intake
Current Nutrition & Food Science COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry New and Investigational Antimicrobials for the Treatment of Severe Skin Infections
Current Drug Therapy Brain Perfusion In Sepsis
Current Vascular Pharmacology Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Current Cancer Drug Targets A Dig Deep to Scout the Pharmacological and Clinical Facet of Garlic (<i>Allium sativum</i>)
Current Traditional Medicine A Review of Dietary Influences on Cardiovascular Health: Part 2: Dietary Patterns
Cardiovascular & Hematological Disorders-Drug Targets Homocysteine Serum Levels as Prognostic Marker of Hepatocellular Carcinoma with Portal Vein Thrombosis
Current Molecular Medicine The Right Ventricle: Biologic Insights and Response to Disease: Updated
Current Cardiology Reviews Anesthetic Pharmacology and Perioperative Considerations for the End Stage Liver Disease Patient
Current Clinical Pharmacology Nanocarriers Loaded with Oxygen to Improve the Protection of the Heart to be Transplanted
Current Pharmaceutical Design Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy
Current Diabetes Reviews